Gland Pharma Hyderabad facility gets 1 observation from USFDA; stock gains 3%
The inspection was concluded with one 483 Observation.14-07-2023
14-07-2023
Gland Pharma Q1 PAT may dip 14.6% YoY to Rs 195.8 cr: Nirmal Bang
Net Sales are expected to increase by 40.3 percent Y-o-Y (up 53.1 percent Q-o-Q) to Rs 1,210.9 crore, according to Nirmal Bang.12-07-2023
Gland Pharma Ltd - 543245 - Reply To The Clarification Sought By BSE
Reply to the Clarification sought by BSE on news item appearing in www.cnbctv18.com12-07-2023
Gland Pharma Ltd - 543245 - Clarification sought from Gland Pharma Ltd
The Exchange has sought clarification from Gland Pharma Ltd on July 10, 2023, with reference to news appeared inwww.cnbctv18.com dated July 10, 2023 quoting "Gland Pharma shares jump most in five months after USFDA approval for methanol poisoning treatment drug"The reply is awaited.10-07-2023
Gland Pharma Ltd - 543245 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund28-06-2023
Gland Pharma gains as investors brush aside USFDA issue
The share touched a 52-week high of Rs 2,718 on June 30, 2022 and a 52-week low of Rs 861.50 on May 22, 2023.28-06-2023
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of the Investor Meetings18-06-2023